Ergoteles’s Zomedica Corp. ZOM Stock Holding History

Ergoteles’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-24,098	Closed	-$5K	–	2252
2022 Q2	$5K	Buy	+24,098	New	+$6.13K	﹤0.01%	1595

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PWMG

Pinnacle Wealth Management Group Plymouth, Michigan $214M AUM 20.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ergoteles's ZOM Position: Q3 2022 in Review

Ergoteles sold out of Zomedica Corp. (ZOM) in Q3 2022, closing a stake of 24,098 shares — an estimated $5K sold.

Ergoteles first reported a position in ZOM in Q2 2022 and held it in 1 quarter. The position peaked at $5K in Q2 2022. 87 funds tracked by Wall St. Rank hold ZOM as of Q3 2022.

Ergoteles reported no remaining Zomedica Corp. position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 24,098 Zomedica Corp. shares in Q3 2022, an estimated $5K.
Ergoteles first reported a position in Zomedica Corp. in Q2 2022 and held it in 1 quarter.
Ergoteles's Zomedica Corp. position peaked at $5K in Q2 2022.
87 funds tracked by Wall St. Rank held Zomedica Corp. as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.